Results from a new study published in Clinical and Translational Immunology found that dual-target antibody therapy can enhance cancer-fighting T cells more effectively than current single-target ...

Researchers say study provides sufficient rationale to further explore the therapeutic uses of SSRIs during infection.

Researchers say study provides sufficient rationale to further explore the therapeutic uses of SSRIs during infection.

Despite promising Phase 3 results, safety concerns, namely liver injury, have impacted Agios stock and could affect ...

A biotech company is attempting to persuade Kansas legislators to modify the state’s controlled substances act in advance of ...

A recent drug discovery could eventually help the visually impaired and those suffering from multiple sclerosis, traumatic stroke, and Alzheimer’s disease regain some of their vision and mental ...

Boston biotech Kojin Therapeutics is closing its doors, citing four funding challenges and a few valuable lessons learned.  ...

Researchers at the University of Toronto see a future where a single injection under the eyelid could replace months of daily ...

Happy V-Day! Gorge on heart-shaped chocolate and ponder the implications of RFK Jr. being sworn in as health secretary. Today, we talk about that, as well as new cancer data from Corbus Pharma, Europe ...

NEW YORK - OS Therapies, Inc. (NYSE-A: OSTX), a small-cap biotech firm with a market capitalization of $42 million focusing on cancer treatment solutions, has announced the completion of its Phase 2b ...

Relay Therapeutics' financial stability is strong, but zero Q3 2024 revenue and rising net losses raise concerns. Find out ...

Backed by Goldman Sachs, Novo Nordisk’s parent company and others, Newleos Therapeutics debuted Thursday with $94 million and ...